Definium Therapeutics Inc. (DFTX)
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
Market open · Delayed 15 min · as of Oct 8, 1:25 PM ET
DFTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.56B
- EPS (TTM)
- -$3.43
- Dividend yield
- None
- 52-week range
- 10.47 – 49.70
- Day range
- 32.84 – 34.88
- Volume / Avg
- 1.02M / 2.14M
- Beta
- —
- Shares outstanding
- 134.37M
- Next earnings
- Nov 5, 2026
52-week range
DFTX stock today
Shares of Definium Therapeutics (DFTX) are trading lower on Oct 8 at $33.90, a drop of 3.39% or $1.19 per share, versus the S&P 500's 0.72% decline. At this level, DFTX sits in the middle of its 52-week range of $10.47 to $49.70: 31.8% below the high, set on Aug 7, 2026 and 223.9% above the low. DFTX is up 162.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 193.1%.
Definium Therapeutics has posted a net loss over the last twelve months (EPS of -$3.43), so its P/E ratio is not meaningful. Definium Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Definium Therapeutics
Company profileDefinium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. Robert Barrow
- Headquarters
- New York, NY
- Employees
- 105
- Website
- definiumtx.com
Financial highlights
Full financialsDefinium Therapeutics reported a net loss of $183.8 million, compared with a loss of $108.7 million a year earlier. Diluted earnings per share came in at -$2.06.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-183.79M | $-108.68M | $-95.73M | $-56.80M | $-93.04M |
| EPS (diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
Analyst forecast
ForecastConsensus (18 analysts)
none
Avg. price target
$71.65+111.36%
- Strong buy 4
- Buy 14
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.54
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-1.44 vs —
DFTX news
All DFTX newsDefinium Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. Subordinate Voting Shares | 10.13 | -6.06% | $1.95B | vs DFTX |
| CRONCronos Group Inc. | 3.18 | -1.85% | $1.17B | vs DFTX |
| TLRYTilray Brands Inc. | 3.55 | -4.46% | $524.61M | vs DFTX |
| GLASGlass House Brands Inc. Subordinate Voting Shares | 4.23 | -17.54% | $398.65M | vs DFTX |
| CGCCanopy Growth Corporation | 0.8299 | -5.32% | $372.87M | vs DFTX |
| OBIOOrchestra BioMed Holdings Inc. | 5.74 | +1.42% | $345.01M | vs DFTX |
| SNDLSNDL Inc. | 1.23 | -1.51% | $303.00M | vs DFTX |
| ACBAurora Cannabis Inc. | 4.46 | 0.00% | $282.36M | vs DFTX |
Indexes, lists and sector
Definium Therapeutics stock FAQ
What is Definium Therapeutics's stock price today?
DFTX last traded at $33.90 as of Oct 8, 1:25 PM EDT, down 3.39% on the day. Prices are delayed at least 15 minutes.
Does Definium Therapeutics pay a dividend?
No. Definium Therapeutics does not currently pay a regular cash dividend.
When is Definium Therapeutics's next earnings date?
Definium Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.54.
Who is Definium Therapeutics's CEO?
Mr. Robert Barrow is the chief executive officer of Definium Therapeutics Inc., which has about 105 employees.
Has DFTX ever split its stock?
Yes. The most recent DFTX stock split was a 1-for-15 split on Aug 29, 2022.
What is the DFTX 52-week high?
The 52-week high for DFTX is $49.70 and the 52-week low is $10.47. The stock is currently 31.8% below its high.